Company Description: Serpass Biologics is a Biotech start up established at Arizona State University, Biodesign Inst. We are developing virus-derived immune and coagulation modulating proteins, a new class of anti-inflammatory drug. The concept is to develop new biologics that target systemic inflammatory diseases, similar to developing anti-bacterial penicillin from mold. We have developed a serine proteinase inhibitor, widely proven in animal models and tested in a prior randomized blinded trial, demonstrating safety and efficacy in patients with unstable coronary syndromes. We have new IP / patents based upon a PEGylated serpin, PEGSerp-1, with 20 years new patent protection. Our goal is to begin production and preclinical safety testing of PEGSerp-1 for application in inflammatory disorders, focusing initially on rare vasculitic disease but with expansion to more common inflammatory disorders such as inflammatory bowel, lupus, and severe lung complications from viral infections such as SARS-CoV-2.